The Powder Room Post

Holiday Eating When You Have Overactive Bladder

By Best Medicine on December 5, 2012

From festive parties to family feasts, it’s the season for holiday eating. But when you have overactive bladder (OAB), it pays to think before you eat. Between the spicy appetizers, chocolate treats, and alcohol-spiked eggnog, you could end up spending your holidays in the bathroom. Plus, you could end up with unwanted pounds. And excess weight may just increase your OAB symptoms.

Fortunately, with a little planning, you can still eat, drink, and be merry this holiday season. You just need to keep OAB in mind when deciding what to indulge in—and what to skip. The guidelines below can help.

Watch Your Weight

During the holidays and all year long, smart food choices help keep your weight in check. The key is choosing foods that pack a lot of nutrition into a relatively small number of calories. Such foods include vegetables, fruits, whole grains, fish, lean meats and poultry, and fat-free or low-fat milk and dairy products.

If you’re overweight, losing weight may lessen your OAB symptoms. One recent study included 338 overweight women with bladder control problems, including OAB. The women were randomly assigned to either an intensive weight-loss program or a control group. After six months, those in the weight-loss group had lost an average of 8 percent of their body weight, compared to 2 percent for the control group. The weight-loss group also had a greater decrease in their frequency of urinary accidents.

Choose Your Foods

Certain foods and drinks have a more direct effect on OAB. Don’t let the wrong choices sabotage your holiday cheer.

First off, learn how to avoid problem foods and beverages that irritate the bladder, contributing to urine leaks. Sensitivity varies from person to person, but these are common culprits:

• Alcoholic beverages

• Carbonated beverages

• Caffeine

• Artificially sweetened drinks

• Coffee (even decaf)

• Tomatoes and tomato products

• Citrus fruits and juices

• Highly spiced foods

• Corn syrup

• Honey

• Chocolate

Managing your fluid intake is key as well. On the one hand, drinking too much makes you urinate more often. On the other hand, drinking too little leads to very concentrated, dark yellow, strong-smelling urine. Such concentrated urine irritates the bladder, and it also promotes the growth of bacteria. Aim for a healthy balance—about six glasses a day, ideally spaced evenly throughout the day. Water is the ideal choice. For a festive drink that’s gentle on your bladder, try cranberry juice.

Plan Your Strategy

Keeping your diet on track at holiday parties and family gatherings is easier if you plan ahead. These strategies may help:

• Don’t arrive hungry. Eat a healthy snack at home first so you aren’t as tempted to nosh on everything in sight.

• Scope out the buffet. Before you pick up a plate, survey the offerings and decide which ones fit into your diet.

• Bring a favorite dish. You’ll know there’s at least one food that you love—and that loves you back—on the table.

Read More

New Study Examines How Health Affects Happiness

By Science Daily on December 3, 2012

ScienceDaily (Nov. 13, 2012) — A new study published in the Journal of Happiness Studies found that the degree to which a disease disrupts daily functioning is associated with reduced happiness.

Lead author Erik Angner, associate professor of philosophy, economics and public policy at George Mason University, worked with an interdisciplinary team of researchers from the University of Alabama at Birmingham, the University of Chicago and the University of Massachusetts Medical School.

Previous research found that many serious medical conditions, including cancer, have a surprisingly small impact on happiness, while certain other conditions, such as urinary incontinence, seem to have a lasting negative effect on happiness.

In their study, Angner and his co-authors explored the difference. They developed a measure called the "freedom-from-debility score" based on four health survey questions explicitly designed to represent limitations in physical activities and in usual role activities because of health problems.

This study is the first to use a direct measure of the degree to which disease disrupts daily functioning.

The authors found that when controlling for demographic and socioeconomic factors in addition to objective and subjective health status, a one-point increase in the freedom-from-debility score (on a scale from 0 to 100) was associated with a three-percent reduction in the odds of reported unhappiness.

For example, a patient with prostate cancer, whose daily functioning is not affected by his condition, might score higher on a happiness scale than a patient with urinary incontinence, whose condition imposes dramatic limitations in daily functioning. Indeed, in an earlier study, the authors found that participants with a history of cancer reported being significantly happier than those with urinary incontinence.

The study was conducted using a sample of 383 older adults recruited from the practices of 39 primary care physicians in Alabama.

"These new results support the notion that health status is one of the most important predictors of happiness," Angner said. "A better understanding of the complex relationship between health status and subjective well-being could have important implications for the care and treatment of patients and could lead to interventions that could dramatically improve patient quality of life."

Angner has separate PhDs in economics and in history and philosophy of science and has written extensively on the philosophy and economics of health, happiness and well-being. He is the author of A Course in Behavioral Economics.

Read More

Adrenoreceptor Shows Potential in Overactive Bladder Treatment

By Sally Robertson on November 14, 2012

Mirabegron, a β₃-adrenoreceptor agonist, has shown 12-month safety, tolerability, and persistence of effect in patients with overactive bladders (OABs), show study findings.

The therapy demonstrated an acceptable safety and tolerability, with improvements in OAB developing after one month and lasting for 12 months, write researchers in European Urology.

The β₃-adrenoreceptors are located in detrusor muscle and facilitate urine storage by inducing detrusor relaxation.

In the 12-month trial, which included 812 patients with OAB, administration of mirabegron 50 mg, mirabegron 100 mg, or an active control - tolterodine extended release (ER) 4 mg - reduced the mean number of micturitions per 24 hours from baseline to a similar extent - by 1.27, 1.41, and 1.39, respectively at study end. The incontinence episodes per 24 hours were also reduced, at respective means of 1.01, 1.24, and 1.26.

The percentage of individuals with at least a 50% reduction from baseline in the mean number of incontinence episodes per 24 hours was 63.7%, 66.3%, and 66.8% in the mirabegron 50 mg, mirabegron 100 mg, and tolterodine ER 4 mg groups, respectively, and the percentage of people with zero incontinence episodes in the corresponding groups was 43.4%, 45.8%, and 45.1%.

Treatment-emergent adverse events (TEAEs) were reported in 59.7%, 61.3%, and 62.6% of the three treatment groups of patients, respectively, with most being mild or moderate. And serious TEAEs were reported in a corresponding 5.2%, 6.2%, and 5.4% of patients.

"Overall, the data support the acceptable safety and tolerability profile of mirabegron in the treatment of OAB at a dose of 50 mg," say Christopher Chapple (Royal Hallamshire Hospital, Sheffield, UK) and colleagues.

"This is the first randomized active-controlled drug trial in patients with OAB to assess the 12-month safety and tolerability of once-daily mirabegron 50 and 100 mg in patients with OAB relative to that of tolterodine ER 4 mg."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Read More

Overactive Bladder (OAB) Impacts 20 Million Women in the U.S., Yet 80 Percent Never Seek Treatment

By PFD Alliance on November 2, 2012

Read More

NAFC Conducts Online Survey to Examine Women’s Perceptions about Overactive Bladder

By News Medical on October 26, 2012

Read More

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies

By PR Newswire on October 22, 2012

NORTHBROOK, Ill., Oct. 22, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ™ (mirabegron) extended-release tablets, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available through U.S. pharmacies.

"The availability of MYRBETRIQ marks an important milestone in our ongoing commitment to urology," said Jim Robinson, senior vice president, Astellas Sales and Marketing. "We are pleased to now be able to provide a portfolio of treatment options for those living with overactive bladder."

MYRBETRIQ is a once-daily, oral beta-3 adrenergic agonist discovered and developed by Astellas. Antimuscarinics are the current OAB treatment standard and work by binding to muscarinic receptors in the bladder and inhibiting involuntary bladder contractions.[1] MYRBETRIQ relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 adrenergic receptors which increases bladder capacity.[2]

"Overactive bladder affects millions of Americans," said Dr. Allen Seftel, outreach council chair of the Urology Care Foundation, the official foundation of the American Urological Association. "Treatment can help, and patients should talk to their doctors to find out the treatment options available to them."

MYRBETRIQ was approved by the U.S. Food and Drug Administration (FDA) on June 28, 2012.

The recommended starting dose for MYRBETRIQ is 25 mg once daily with or without food. MYRBETRIQ 25 mg is effective within eight weeks; based on individual efficacy and tolerability, the dose may be increased to 50 mg once daily.[3]

USE of MYRBETRIQ MYRBETRIQ™ (mirabegron) is a prescription medicine for adults used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION MYRBETRIQ may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. It is recommended that your doctor check your blood pressure while you are taking MYRBETRIQ. MYRBETRIQ may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream. Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines such as thioridazine (Mellaril® and Mellaril S®), flecainide (Tambocor™), propafenone (Rythmol®), digoxin (Lanoxin®).* MYRBETRIQ may affect the way other medicines work, and other medicines may affect how MYRBETRIQ works. Before taking MYRBETRIQ, tell your doctor if you have liver or kidney problems. In clinical studies, the most common side effects seen with MYRBETRIQ included increased blood pressure, common cold symptoms (nasopharyngitis), urinary tract infection and headache. For further information please talk to your healthcare professional and see accompanying Product Information for MYRBETRIQ (mirabegron). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. *All other trademarks or registered trademarks are the property of their respective owners.

About Overactive Bladder

According to the National Association for Continence, one in five adults has overactive bladder.[4] However, recent studies have found that many more people may be affected, and have not talked to their physicians out of embarrassment or belief that OAB cannot be treated.[5] For people with OAB, inappropriate signals are sent to the muscles in the bladder causing them to contract before the bladder is full. These bladder contractions may cause strong, sudden urges, and a frequent need to go to the bathroom, sometimes without any advance warning.[6] Many patients cope with their symptoms by restricting fluids, carrying extra clothing and "mapping" bathroom locations wherever they go.

About Astellas Urology

Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The company is committed to being a global category leader in urology and providing solutions for physicians and patients through the discovery of new treatments for OAB and other urologic conditions. Astellas currently markets the number one branded OAB treatment in the U.S. For more information about Astellas Pharma US, Inc., please visit www.astellas.us. [1] Yamaguchi O. Antimuscarinics and Overactive Bladder: Other Mechanism of Action. Neurourology and Urodynamics 2010; 29:112–115 [2] MYRBETRIQ Prescribing Information, Section 12.1, June 2012 [3] MYRBETRIQ Prescribing Information, Section 2.1, June 2012 [4] National Association for Continence. Accessed May 29, 2012. http://www.nafc.org/media/media-kit/facts-statistics [5] Kin S, et al. Medical Visits Among Adults with Symptoms Commonly Associated with an Overactive Bladder. BJU International. 2006;97:551-554. [6] Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology & Urodynamics. 2002;21(2):167-78. SOURCE Astellas Pharma US, Inc.

Read More

Mirabegron Receives Positive CHMP Opinion for Treatment of Overactive Bladder Symptoms

By Julia Holt on October 19, 2012

Chertsey, England (ots/PRNewswire) -

ASTELLAS PHARMA EUROPE Ltd. announced today that the Committee
for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) has adopted a positive opinion, recommending the
granting of a marketing authorisation for BETMIGA[TM] (mirabegron)
for the symptomatic treatment of urgency, increased micturition
frequency and/or urgency incontinence as may occur in adult patients
with overactive bladder (OAB) syndrome.

The opinion now needs ratification by decision of the European
Commission which is expected within the next 74-90 days. If approved,
mirabegron will be the first in a new class of OAB treatment,
offering healthcare professionals an alternative option to
antimuscarinics (currently the only licensed oral treatment option)
when treating patients with OAB.

Mirabegron is a once daily oral beta3-adrenoceptor agonist with a
distinct mechanism of action compared to antimuscarinics, the current
treatment standard.[1] Antimuscarinics work by binding to muscarinic
receptors in the bladder and inhibiting involuntary bladder
contractions. Mirabegron works by stimulating the beta3 receptors in
the detrusor muscle of the bladder[2] causing relaxation of the
bladder muscle during the storage phase of the micturition cycle.
This improves the storage capacity of the bladder without inhibiting
bladder voiding.[3]

The positive opinion was reached after the CHMP reviewed
comprehensive clinical trial evidence from 7 phase II / III studies
in which over 5,000 patients received mirabegron, including three
Phase III double-blind, randomised controlled trials conducted in the
US and Europe-Australia.[4],[5],[6] In the trials, mirabegron
demonstrated superior efficacy compared to placebo in the treatment
of symptoms of OAB, with patients needing to visit a toilet
significantly less frequently and experiencing fewer incontinence
episodes.[4],[5],[ 6] In terms of quality of life, treatment of the
symptoms of OAB with mirabegron once daily has also demonstrated
statistically significant improvements over placebo on quality of
life measures such as treatment satisfaction and symptom bother.[7]

Astellas Pharma Europe Ltd. is an established leader in urology
in Europe, committed to improving the lives of patients with
urological conditions. Its current urology portfolio includes
treatments for benign prostatic hyperplasia (BPH), overactive bladder
(OAB) and prostate cancer. With a strong emphasis on research and
development, Astellas is dedicated to finding new treatments to meet
unmet medical needs and has a number of treatments for urological
conditions in development. As part of its ongoing commitment to the
field, Astellas also provides and supports a wide range of
educational opportunities for those working in the field of urology,
designed to progress professional expertise and improve patient
outcomes.

Notes to editors

About overactive bladder

Overactive bladder (OAB) is characterised by symptoms of urinary
urgency, with or without urgency incontinence, usually with increased
daytime frequency and nocturia (awakening at night one or more times
to empty the bladder).[8]

OAB is a common condition. A survey of over 16,000 adult men and
women in six European countries revealed that 17% of respondents had
symptoms of OAB.[9] Prevalence of OAB increases with age, with 30% to
40% of those aged over 75 years affected.[9] OAB can also have a
major impact on quality of life. In the survey, a majority (65%) of
respondents indicated their daily lives were adversely affected.[9]

About mirabegron

Mirabegron is a once daily oral beta3-adrenoceptor agonist
discovered and developed by Astellas. It is the first compound
submitted for regulatory approval in this new class of treatment for
OAB, using a distinct mechanism of action compared to
antimuscarinics, the current treatment standard.[1] Antimuscarinics
work by binding to muscarinic receptors in the bladder and inhibiting
involuntary bladder contractions. Mirabegron works by stimulating the
beta3 receptors in the detrusor muscle of the bladder causing
relaxation of the bladder muscle during the storage phase of the
micturition cycle.[2] This improves the storage capacity of the
bladder without impeding bladder voiding.[3]

Astellas submitted a New Drug Application and Market
Authorisation Application for mirabegron to the U.S. Food and Drug
Administration and the European Medicines Agency in August 2011 and
received FDA approval on 28th June 2012, and CHMP opinion today. In
Japan, Astellas was granted marketing approval under the trade name
of BETANIS(R) tablet in July 2011. Additionally, there is a recently
completed multiregional Phase III study in China, Korea, Taiwan, and
India.

About Astellas Pharma Europe Ltd.:

Astellas Pharma Europe Ltd., located in the UK, is the European
headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative pharmaceuticals.
The organisation's focus is to deliver outstanding R&D and marketing
to continue growing in the world pharmaceutical market. Astellas
Pharma Europe Ltd. is responsible for 21 affiliate offices located
across Europe, the Middle East and Africa, an R&D site and three
manufacturing plants. The company employs approximately 4,300 staff
across these regions. For more information about Astellas Pharma
Europe, please visit http://www.astellas.eu.

References

1) Khullar V et al. Efficacy of mirabegron in patients with and without
prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a
prospective, randomised European-Australian phase III trial. EAU 2012 Abstract
AM12-2389: 684
2) Takasu T et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4?-{2-[(
2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective
beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007; 321: 642-7
3) Tyagi P et al. Mirabegron: safety review Expert Opin. Drug Safety 2011;10.2:
287-294
4) Nitti V et al. The efficacy and tolerability of mirabegron, a potent and
selective beta3-adrenoceptor agonist, compared with placebo and tolterodine slow
release in patients with overactive bladder - results from a North American Phase III
trial. Presented at ICS 2011.
5) Khullar V et al. The efficacy and tolerability of mirabegron, a potent and
selective beta3-adrenoceptor agonist, compared with placebo and tolterodine slow
release in patients with overactive bladder - results from a European-Australian Phase
III trial. Presented at ICS 2011
6) Van Kerrebroeck P, Barkin J, Castro-Diaz D et al. Randomised, double-blind,
placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25
mg and 50 mg once daily in overactive bladder (OAB). Presented at ICS 2012.
7) Nitti V et al. Mirabegron improves patient-reported outcomes in patients with
overactive bladder syndrome - results from a North-American study. Presented at AUA
2011
8) Abrams P. et al. Reviewing the ICS 2002 Terminology Report: The Ongoing
Debate. Neurourol Urodyn 2006; 25: 293-294
9) Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an
overactive bladder and how are they managed? A population-based prevalence study. BJU
Int 2001; 87(9): 760-6

ots Originaltext: Astellas Pharma Europe Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information please contact: Julia Holt, Red Door
Communications, jholt@rdcomms.com , Tel: +44(0)20-8392-8052, Mobile:
+44(0)7788-441422; Mindy Dooa, Astellas Pharma Europe Ltd.,
Mindy.Dooa@astellas.com , Tel: +44(0)203-379-8035, Mobile:
+44(0)7826-912-339

Quelle: OTS

Read More

Le Botox, une solution aux problèmes d'incontinence chez la femme

By Amber Moore on October 8, 2012

Une étude américaine publiée dans le New England Journal of Medicine montre que les injections de Botox sont tout aussi efficaces que certains médicaments prescrits contre l'incontinence urinaire.

Le Botox a déjà reçu l'aval de la Food and Drug Administration américaine pour traiter l'incontinence urinaire due à une lésion nerveuse suite à un traumatisme de la colonne vertébrale. Les médecins américains ont désormais la possibilité de recourir au Botox pour traiter les problèmes de vessie dus à d'autres pathologies, ou si les médicaments oraux ne faisaient plus effet.

L'étude a pris en compte 250 femmes souffrant d'incontinence. Elles furent divisées en deux groupes, le premier prenant quotidiennement des médicaments oraux (des anticholinergiques), tandis que le second se voyait administrer des injections de Botox dans la vessie. 

Au final, le Botox s'est avéré aussi efficace que les médicaments oraux pour réduire les épisodes d'incontinence urinaire à six mois.

A six semaines, 70% des femmes des deux groupes confiaient souffrir de trois fuites urinaires quotidiennes en moyenne, alors qu'elles étaient à cinq en début d'étude. 

De plus, deux fois plus de femmes figurant dans le groupe traité au Botox voyaient leur incontinence disparaître.

Cependant, le site spécialisé WebMD explique les effets du Botox ne sont pas pérennes, et que les patientes devront renouveler les injections neuf mois plus tard pour contrôler les symptômes.

Ces résultats ont été présentés au cours de la conférence annuelle de l'American Urogynecologic Society à Chicago, qui s'est tenue du 3 au 6 octobre.

Pour en Savoir Plus

Botox Injections May Be a New Treatment for Overactive Bladders

By Amber Moore on October 8, 2012

Botox injections are as effective as oral medication for urinary incontinence, says a new study.

Urinary incontinence is the loss of bladder control. The condition affects millions of women around the world. Some women experience mild symptoms like passing small amounts of urine while coughing or running while others have more severe symptoms like an intense and sudden desire to urinate before leaking large amounts of urine.

The UK recently approved Allergan Inc.'s Botox (Botulinum Toxin Type A) for urinary incontinence in patients who have multiple sclerosis and spinal cord injuries.

"This is the first study to compare the effectiveness of Botox treatments to oral medication. Previously, Botox was reserved for women who had tried oral medications but found them ineffective. Because we included some women who had not been treated with oral medication before, these results suggest that Botox could be discussed as an option for first line treatment," said study senior author Susan F. Meikle, from the Contraception and Reproductive Health Branch of the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development.

The study included 250 women who were diagnosed with urinary incontinence. The participants were randomly divided into two groups with one group receiving Botox injection and also placebo pills for six months while the other group got saline injection and medications to treat urinary incontinence.

Participants then had to record the number of incontinence episodes that they had each month. They also had to answer a questionnaire about their quality of life and symptoms.

By the end of the study, about 70 percent of the women said their symptoms had reduced. Researchers asked the participants to stop taking the treatment after six months but continued to monitor their progress. After nine months, about 52 percent women in the Botox group reported fewer symptoms compared to about 32 percent for the non-Botox group. After a year of treatment, 38 percent of the Botox group said their condition had improved compared to about 25 percent of the group who did not use Botox.

Side Effects

After two months of treatment, women in the Botox group had to use a catheter to empty their bladder and were more likely to experience urinary tract infections than women who were on oral pills (33 percent versus 13 percent). But, the oral pill group was more likely to report symptoms of dry mouth.

"Any treatment that slows the bladder will tend to impair bladder emptying. Incomplete emptying can lead to urinary infections or retention and the need to catheterize to empty," said Dr. Niall T.M. Galloway, from the National Association for Continence based in Charleston, S.C., as reported by ABC News.

The study was published in the New England Journal of Medicine.

Read More

Gelnique® (gel de chlorure d'oxybutynine à 10 %) est maintenant disponible au Canada

By (CNW) on September 12, 2012

- Le premier et le seul gel pour le traitement de la vessie hyperactive

- Une option de traitement rapide et commode qui permet aux patients de traiter la vessie hyperactive sans avoir à prendre une pilule

OAKVILLE, ON, le 12 sept. 2012 /CNW/ - Watson Canada a annoncé aujourd'hui que Gelnique® (gel de chlorure d'oxybutynine), le premier gel topique pour le traitement de la vessie hyperactive (VHA), est maintenant disponible au Canada. Gelnique offre aux patients une nouvelle alternative aux traitements actuels par voie orale, avec une très faible incidence d'effets secondaires, tels que la bouche sèche.

Gelnique est un gel clair et inodore qui sèche rapidement. On l'applique une fois par jour sur les cuisses, l'abdomen, le haut des bras ou les épaules. On frotte une dose d'un gramme de Gelnique sur la peau pour la faire pénétrer comme une crème, et une dose constante d'oxybutynine est libérée pendant une période de 24 heures.

« La nouvelle formulation de Gelnique sous forme de gel représente une importante nouvelle option de traitement pour les patients qui ont une vessie hyperactive, » déclare le Dr Sender Herschorn, professeur et directeur, département d'urologie de l'Université de Toronto. « Gelnique contient de l'oxybutynine, le même ingrédient que l'on retrouve dans de nombreux traitements oraux disponibles, qui est bien établi comme un traitement sûr et efficace de la VHA. Cependant, parce Gelnique est absorbé à travers la peau et non pris par la bouche, les patients pourraient éprouver des effets secondaires anticholinergiques limités. »

Les thérapies actuelles par voie orale pour la VHA sont souvent associées à des effets secondaires préoccupants, comme la bouche sèche et la constipation graves, amenant souvent les patients à cesser de les utiliser. Contrairement aux traitements par voie orale, Gelnique est administré par voie transdermique et il a été démontré qu'il cause peu d'effets indésirables anticholinergiques. Dans les essais cliniques avec Gelnique, aucun patient n'a interrompu le traitement en raison de sécheresse de la bouche.

PLUS QU'UN DÉSAGRÉMENT OU UN EMBARRAS

La vessie hyperactive est une affection fréquente et débilitante, caractérisée par une soudaine et inconfortable envie d'uriner même quand la vessie n'est pas pleine. Elle se solde souvent par une perte inattendue d'urine, des accidents d'incontinence et l'embarras qui en résulte.

Au Canada, près d'une personne sur cinq âgée de plus de 35 ans souffre de VHA. Plus qu'un inconvénient ou un embarras, la VHA est associée à des risques accrus pour la santé et une diminution de la qualité de vie. Les patients atteints de VHA présentent également des taux plus élevés d'hypertension, d'obésité et même d'arthrite.

Bien que la prévalence de la VHA est légèrement plus élevée chez les femmes, un homme sur six souffre de vessie hyperactive (21,2 vs 14,8 pour cent).

LA VHA AFFECTE LES RELATIONS PERSONNELLES ET LA QUALITÉ DE VIE

Les hommes et les femmes atteints de VHA sont beaucoup plus susceptibles de rapporter une diminution de l'activité sexuelle et du plaisir sexuel en raison de symptômes urinaires.

Il a été démontré que la VHA pouvait réduire le désir sexuel et la capacité à atteindre l'orgasme chez la femme et qu'elle peut être associée à une prévalence accrue de la dysfonction érectile et une réduction du plaisir sexuel chez l'homme. Les partenaires des patients rapportent que la VHA suscite d'importantes émotions, incluant la gêne, l'anxiété, la colère, l'inquiétude, la frustration et la sympathie.

« La vessie hyperactive affecte non seulement la santé dans son ensemble, mais également l'intimité sexuelle, les relations amoureuses et la confiance en soi, » dit Maureen McGrath, infirmière-conseil en continence. « Tous les patients devraient parler à leur médecin de leur santé sexuelle lorsqu'ils désirent être traités pour une vessie hyperactive, car cela peut sérieusement affecter leur qualité de vie. »

À PROPOS DE GELNIQUE

Gelnique est indiqué pour le traitement de la VHA accompagnée de symptômes d'incontinence urinaire par impériosité, de miction impérieuse et de mictions fréquentes.

Dans une étude de phase 3 de 12 semaines, un gramme de Gelnique une fois par jour était supérieur au placebo pour soulager les symptômes de VHA, incluant une réduction des épisodes d'incontinence et de la fréquence des mictions et une augmentation du volume d'urine par miction. Le traitement a été bien toléré dans cette étude avec une faible incidence d'effets secondaires pour la plupart bénins et aucun événement indésirable grave. Les effets indésirables les plus fréquents liés au traitement (> 2 pour cent et supérieur au placebo) étaient la bouche sèche et des réactions au site d'application (5,4 pour cent).

Des études de pharmacologie supplémentaires ont montré que prendre une douche une heure ou plus après l'application ou appliquer une crème solaire à base non huileuse 30 minutes avant ou après l'application de Gelnique ne modifie pas de façon importante l'absorption du médicament.

Gelnique a considérablement amélioré la qualité de vie dans les domaines des déplacements, de l'activité physique, des relations sociales et de la santé émotionnelle.

Pour des renseignements posologiques complets, veuillez visiter WatsonPharmaCompany.ca.

À PROPOS DE WATSON PHARMA COMPANY

Watson Pharma Company est la nouvelle filiale canadienne de Watson Pharmaceuticals, Inc. Elle a été fondée en 2011 et son siège social est situé à Oakville, en Ontario, au Canada. Elle s'occupe du marketing, de la vente et de la distribution de produits pharmaceutiques de marque sur le marché canadien. Watson se concentre à offrir des produits innovateurs dans les domaines thérapeutiques de l'urologie et de la santé des femmes. Comme filiale de Watson Pharmaceuticals, elle profite des capacités sophistiquées de R et D et de production de Watson et de l'une des plus importantes chaînes mondiales d'approvisionnement dans l'industrie. Pour le communiqué de presse et d'autres informations sur la compagnie, veuillez visiter le site Web de Watson Pharma Company à www.WatsonPharmaCompany.ca

SOURCE : Watson Pharma Company

Renseignements :

Michelle MacLeod
Hill+Knowlton Strategies
416.413.4744 / Michelle.macleod@hkstrategies.ca

Pour en Savoir Plus